Current Progress Towards the Application of Aptamers in Pancreatic Adenocarcinoma

Dong-mei HAN,Tang-gang DENG,Mao YE
DOI: https://doi.org/10.16605/j.cnki.1007-7847.2018.04.011
2018-01-01
Abstract:Pancreatic adenocarcinoma is one of the most lethal cancers. It is of great significance to achieve early diagnosis and treatment for pancreatic adenocarcinoma. Aptamers are single-stranded DNA or RNA with high affinity and specificity for target molecules by SELEX. They are often termed as chemical antibodies, and they not only have the characteristics of antibodies, but also have several advantages over general antibodies, including easy modification, low cost, non-immunogenicity and diverse targets. Therefore, they have the great potential in diagnosis and treatment of tumors. So far, kinds of aptamers specifically targeted the pancreatic cancer have been screened out. Herein, aptamers targeted the pancreatic cancer and various aptamer-based diagnostic and therapeutic strategies were reviewed. What's more, the current problems, challenges, and future perspectives in this field were also discussed.
What problem does this paper attempt to address?